Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24253567 | 0.93 | GABRA1 (0.39) | GABRA1GABRB2ALDH1A1TSHRPRMT5 | |
| SCHEMBL23420944 | 0.90 | ALDH1A1 (0.42) | GABRA1GABRB2ALDH1A1TSHREPHX1 | |
| SCHEMBL19601665 | 0.86 | GABRA1 (0.43) | GABRA1GABRB2ALDH1A1TSHREPHX1 | |
| SCHEMBL16245889 | 0.84 | GABRA1 (0.37) | GABRA1GABRB2ALDH1A1TSHRPRMT5 | |
| SCHEMBL24115980 | 0.81 | NPC1 (0.36) | ALDH1A1P2RX3PRMT5WDR77NPC1 | |
| SCHEMBL13146614 | 0.80 | P2RX3 (0.36) | ALDH1A1P2RX3TSHRPRMT5WDR77 | |
| SCHEMBL22993306 | 0.77 | GRIN2B (0.38) | P2RX3PRMT5WDR77 | |
| SCHEMBL16245884 | 0.77 | GABRA1 (0.44) | GABRA1GABRB2ALDH1A1NPC1RAB9A | |
| SCHEMBL21893908 | 0.77 | ESR1 (0.36) | P2RX3TSHRPRMT5WDR77NPC1 | |
| SCHEMBL5018746 | 0.75 | ACACB (0.48) | NPC1RAB9ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-11613527-B2 | Enzyme inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-03-28 | — | — | US | disclosed |
| US-20220048894-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | GABRA1 3274/4885GABRB2 3312/4885ALDH1A1 1622/4885 |
| US-11613527-B2 | Enzyme inhibitors | SERPINB1, KLKB1, SERPINE1 | GABRA1 3274/4885GABRB2 3312/4885ALDH1A1 1622/4885 |
| US-20220048894-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | GABRA1 3274/4885GABRB2 3312/4885ALDH1A1 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.